ESC 365 - Novel drugs in heart failure: what's on the horizon?

HFA Premium Access

Novel drugs in heart failure: what's on the horizon?

Session: Novel drugs - how do they work?

Topic: Miscellaneous

Speaker: Professor C. Maack (Wuerzburg, DE)

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Professor Christoph Maack

University Clinic Wuerzburg, Wuerzburg (Germany)

37 presentations

3 followers

5 more presentations in this session

Effects of serelaxin on a systolic cardiac dysfunction induced by isoproterenol in mice with increased cardiac aldosterone

Speaker: Doctor G. Billebeau (Paris, FR)

Why treatment with natriuretic peptide analogs failed to fulfill our expectations? - receptor expression and function in a failing heart.

Speaker: Doctor K. Kodziszewska (Warsaw, PL)

ORM-3819 promotes cardiac contractility on a dual mechanism of action: troponin-C dependent calcium sensitization is supported by selective PDE III inhibition

Speaker: Doctor L. Nagy (Debrecen, HU)

Vepoloxamer (purified poloxamer-188) improves LV function, limits cardiomyocyte calcium overload and restores integrity of calciu cycling proteins in myocardium of dogs with advanced heart failure

Speaker: Professor H. Sabbah (Detroit, US)

Targeting HDACs in heart failure.

Access the full session

Novel drugs - how do they work?

Speakers: Professor C. Maack, Doctor G. Billebeau, Doctor K. Kodziszewska, Doctor L. Nagy, Professor H. Sabbah

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources